Stockreport

Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update

Artelo Biosciences, Inc.  (ARTL) 
US:NASDAQ Investor Relations: artelobio.com/investors
PDF Complete Enrollment of Phase 1 CAReS Trial Anticipated by End of First Quarter of Calendar Year 2022 $26.4 Million in Cash and Marketable Securities as of November 30 [Read more]